Background <p>Invasive infections by <i>Nocardia farcinica</i>, <i>Aspergillus species (spp</i>.<i>)</i> and <i>Candida dubliniensis</i> are rare infectious complications in patients diagnosed with multiple myeloma.</p> <p>Case presentation.</p> <p>In this case report, we describe a patient who received three lines of therapy, with proteasome inhibitors, corticosteroids, cyclophosphamide and lenalidomide, and who was concurrently infected with these three opportunistic pathogens. A blood stream infection with <i>C. dubliniensis</i> was treated with 4 weeks of anidulafungin. <i>Aspergillus spp.</i> was treated for 12 weeks with voriconazole. <i>N. farcinica</i> treatment was continued indefinitely with co-trimoxazole and moxifloxacin after regression at discharge of brain abscesses and the pulmonary aspergilloma.</p> Conclusion <p>The diagnostic challenges and management in this particularly vulnerable patient are highlighted.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

More than meets the eye: Nocardia farcinica, Candida dubliniensis and Aspergillus spp. co-infection in a patient with multiple myeloma treated with multiple treatment regimens

  • Lotte Vrijders,
  • Erwin Ho,
  • Danielle Van der Beek,
  • Inge Vrelust,
  • Heleen Nailis

摘要

Background

Invasive infections by Nocardia farcinica, Aspergillus species (spp.) and Candida dubliniensis are rare infectious complications in patients diagnosed with multiple myeloma.

Case presentation.

In this case report, we describe a patient who received three lines of therapy, with proteasome inhibitors, corticosteroids, cyclophosphamide and lenalidomide, and who was concurrently infected with these three opportunistic pathogens. A blood stream infection with C. dubliniensis was treated with 4 weeks of anidulafungin. Aspergillus spp. was treated for 12 weeks with voriconazole. N. farcinica treatment was continued indefinitely with co-trimoxazole and moxifloxacin after regression at discharge of brain abscesses and the pulmonary aspergilloma.

Conclusion

The diagnostic challenges and management in this particularly vulnerable patient are highlighted.